Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Diego Pilati und 17 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: Receptors, Fc, Toll-Like Receptor 9, Histocompatibility Antigens Class I, Oligodeoxyribonucleotides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Norges Forskningsråd, Helse Sør-Øst RHF, Innovationsfonden.
Abstract (Originalsprache)
CpG-oligodeoxynucleotide (CpG ODN)-based Toll-like receptor (TLR) agonists are promising immunostimulatory adjuvants; however, low entry into TLR-rich cellular endosomal compartments and poor lymphatic accumulation limit clinical translation. In this work, we introduce a recombinant human serum albumin (rHA)-CpG ODN covalent conjugate (rHA-CpG) designed to exploit the neonatal Fc receptor (FcRn)-driven albumin cellular sorting pathway to maximize CpG delivery into TLR9-rich endosomes and accumulate in lymph nodes. Site-selective conjugation of CpG to albumin cysteine 34, distant from its main FcRn-binding interface, resulted in a retained pH-dependent human FcRn binding, and receptor-driven endosomal trafficking in a cellular recycling assay. Induction of tumor necrosis factor (TNF) secretion in THP-1 cells and interferon alpha (IFN-α) in human hematopoietic stem and progenitor cell (HSPC)-derived plasmacytoid dendritic cells (pDCs), in contrast, to a myeloid differentiation primary response 88 (MyD88) and TLR9 knockout cells, respectively, support TLR9-engagement. The rHA-CpG construct induced greater TNF-α than free CpG ODN in mouse RAW 264.7 cells, and in human peripheral blood mononuclear cells (PBMCs) and expansion of classical (CD14+CD16-) monocytes. Furthermore, greater accumulation of Cy5.5-labelled CpG in the inguinal (>3-fold) and axillary (>18-fold) lymph nodes was observed when conjugated to rHA compared to an unconjugated rHA/CpG mix following subcutaneous injection in mice. Moreover, increased LN accumulation of an rHA variant engineered with high FcRn-binding affinity supports an FcRn-driven mechanism. Demonstration of FcRn-mediated albumin targeting at intra- and extracellular sites provides the mechanistic basis for the potent immune induction observed using the novel rHA-CpG conjugate design class introduced in this work.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
- Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine and Department of Pharmacology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norwa…
- Immuno-Oncology and Immunotherapy Group, Biomedical Research Institute Hospital Universitario 12 de Octubre (imas12), Madrid, Spain; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12…
- Leadartis, S.L., Madrid, Spain.
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark. Electronic address: kenh@inano.au.dk.
Förderung
- Norges Forskningsråd
- Helse Sør-Øst RHF
- Innovationsfonden
- Danmarks Frie Forskningsfond
- Independent Research Fund Denmark
- Ministerio de Ciencia e Innovación
Zitieren
APA
Pilati, D., Agyei, E. K., Elkhashab, M., Fuchs, E., Nielsen, I. H., Bjerg, T. W., Anthi, A. K., Jiménez-Reinoso, A., Iversen, M. B., Pohl, L., Narita, R., Frago, S., Jakobsen, M. R., Andersen, J. T., Degn, S. E., Paludan, S. R., Alvarez-Vallina, L., & Howard, K. A. (2025). Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108508
Vancouver
Pilati D, Agyei EK, Elkhashab M, Fuchs E, Nielsen IH, Bjerg TW, et al. Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108508
BibTeX
@article{Pilati2025,
author = {Pilati, Diego and Agyei, Eugene Kusi and Elkhashab, Marwa and Fuchs, Elisabeth and Nielsen, Ian Helstrup and Bjerg, Tobias Wang and Anthi, Aina Karen and Jiménez-Reinoso, Anaïs and Iversen, Marie Beck and Pohl, Layla and Narita, Ryo and Frago, Susana and Jakobsen, Martin R and Andersen, Jan Terje and Degn, Søren E and Paludan, Søren R and Alvarez-Vallina, Luis and Howard, Kenneth A},
title = {Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108508}
}
EUVIMED